IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v13y2022i1d10.1038_s41467-022-33793-w.html
   My bibliography  Save this article

Co-expression of a PD-L1-specific chimeric switch receptor augments the efficacy and persistence of CAR T cells via the CD70-CD27 axis

Author

Listed:
  • Le Qin

    (Chinese Academy of Sciences)

  • Yuanbin Cui

    (Chinese Academy of Sciences)

  • Tingjie Yuan

    (The Fifth Affiliated Hospital of Guangzhou Medical University
    Guangzhou Laboratory)

  • Dongmei Chen

    (Chinese Academy of Sciences)

  • Ruocong Zhao

    (Chinese Academy of Sciences)

  • Shanglin Li

    (Chinese Academy of Sciences)

  • Zhiwu Jiang

    (Chinese Academy of Sciences)

  • Qiting Wu

    (Chinese Academy of Sciences)

  • Youguo Long

    (Chinese Academy of Sciences)

  • Suna Wang

    (Chinese Academy of Sciences)

  • Zhaoyang Tang

    (Guangdong Zhaotai InVivo Biomedicine Co. Ltd)

  • Huixia Pan

    (Guangdong Zhaotai InVivo Biomedicine Co. Ltd)

  • Xiaoping Li

    (the Third Affiliated Hospital of Sun Yat-sen University)

  • Wei Wei

    (Guangdong Cord Blood Bank)

  • Jie Yang

    (Guangdong Women and Children Hospital, Panyu)

  • Xuequn Luo

    (Sun Yat-Sen University)

  • Zhenfeng Zhang

    (the Second Affiliated Hospital of Guangzhou Medical University)

  • Qiannan Tang

    (The University of Hong Kong)

  • Pentao Liu

    (The University of Hong Kong)

  • Robert Weinkove

    (Malaghan Institute of Medical Research)

  • Yao Yao

    (Chinese Academy of Sciences)

  • Dajiang Qin

    (The Fifth Affiliated Hospital of Guangzhou Medical University)

  • Jean Paul Thiery

    (Guangzhou Laboratory)

  • Peng Li

    (Chinese Academy of Sciences
    Chinese Academy of Sciences
    Bioland Laboratory (Guangzhou Regenerative Medicine and Health Guangdong Laboratory))

Abstract

Co-expression of chimeric switch receptors (CSRs) specific for PD-L1 improves the antitumor effects of chimeric antigen receptor (CAR) T cells. However, the effects of trans-recognition between CSRs and PD-L1 expressed by activated CAR T cells remain unclear. Here, we design a CSR specific for PD-L1 (CARP), containing the transmembrane and cytoplasmic signaling domains of CD28 but not the CD3 ζ chain. We show that CARP T cells enhance the antitumor activity of anti-mesothelin CAR (CARMz) T cells in vitro and in vivo. In addition, confocal microscopy indicates that PD-L1 molecules on CARMz T cells accumulate at cell-cell contacts with CARP T cells. Using single-cell RNA-sequencing analysis, we reveal that CARP T cells promote CARMz T cells differentiation into central memory-like T cells, upregulate genes related to Th1 cells, and downregulate Th2-associated cytokines through the CD70-CD27 axis. Moreover, these effects are not restricted to PD-L1, as CAR19 T cells expressing anti-CD19 CSR exhibit similar effects on anti-PSCA CAR T cells with truncated CD19 expression. These findings suggest that target trans-recognition by CSRs on CAR T cells may improve the efficacy and persistence of CAR T cells via the CD70-CD27 axis.

Suggested Citation

  • Le Qin & Yuanbin Cui & Tingjie Yuan & Dongmei Chen & Ruocong Zhao & Shanglin Li & Zhiwu Jiang & Qiting Wu & Youguo Long & Suna Wang & Zhaoyang Tang & Huixia Pan & Xiaoping Li & Wei Wei & Jie Yang & Xu, 2022. "Co-expression of a PD-L1-specific chimeric switch receptor augments the efficacy and persistence of CAR T cells via the CD70-CD27 axis," Nature Communications, Nature, vol. 13(1), pages 1-14, December.
  • Handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-33793-w
    DOI: 10.1038/s41467-022-33793-w
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-022-33793-w
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1038/s41467-022-33793-w?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Roy S. Herbst & Jean-Charles Soria & Marcin Kowanetz & Gregg D. Fine & Omid Hamid & Michael S. Gordon & Jeffery A. Sosman & David F. McDermott & John D. Powderly & Scott N. Gettinger & Holbrook E. K. , 2014. "Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients," Nature, Nature, vol. 515(7528), pages 563-567, November.
    2. Fan Zou & Lijuan Lu & Jun Liu & Baijin Xia & Wanying Zhang & Qifei Hu & Weiwei Liu & Yiwen Zhang & Yingtong Lin & Shuliang Jing & Mei Huang & Bifen Huang & Bingfeng Liu & Hui Zhang, 2019. "Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56," Nature Communications, Nature, vol. 10(1), pages 1-14, December.
    3. Sissy E. Wamaitha & Katarzyna J. Grybel & Gregorio Alanis-Lobato & Claudia Gerri & Sugako Ogushi & Afshan McCarthy & Shantha K. Mahadevaiah & Lyn Healy & Rebecca A. Lea & Miriam Molina-Arcas & Liani G, 2020. "IGF1-mediated human embryonic stem cell self-renewal recapitulates the embryonic niche," Nature Communications, Nature, vol. 11(1), pages 1-16, December.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Jing Liu & Xia Bu & Chen Chu & Xiaoming Dai & John M. Asara & Piotr Sicinski & Gordon J. Freeman & Wenyi Wei, 2023. "PRMT1 mediated methylation of cGAS suppresses anti-tumor immunity," Nature Communications, Nature, vol. 14(1), pages 1-15, December.
    2. Kristian Bjørn Hessellund & Ganggang Xu & Yongtao Guan & Rasmus Waagepetersen, 2022. "Second‐order semi‐parametric inference for multivariate log Gaussian Cox processes," Journal of the Royal Statistical Society Series C, Royal Statistical Society, vol. 71(1), pages 244-268, January.
    3. Elaine Lai-Han Leung & Run-Ze Li & Xing-Xing Fan & Lily Yan Wang & Yan Wang & Zebo Jiang & Jumin Huang & Hu-Dan Pan & Yue Fan & Hongmei Xu & Feng Wang & Haopeng Rui & Piu Wong & Hermi Sumatoh & Michae, 2023. "Longitudinal high-dimensional analysis identifies immune features associating with response to anti-PD-1 immunotherapy," Nature Communications, Nature, vol. 14(1), pages 1-9, December.
    4. Weicai Huang & Yuming Jiang & Wenjun Xiong & Zepang Sun & Chuanli Chen & Qingyu Yuan & Kangneng Zhou & Zhen Han & Hao Feng & Hao Chen & Xiaokun Liang & Shitong Yu & Yanfeng Hu & Jiang Yu & Yan Chen & , 2022. "Noninvasive imaging of the tumor immune microenvironment correlates with response to immunotherapy in gastric cancer," Nature Communications, Nature, vol. 13(1), pages 1-14, December.
    5. Matthew T. Campbell & Surena F. Matin & Alda L. Tam & Rahul A. Sheth & Kamran Ahrar & Rebecca S. Tidwell & Priya Rao & Jose A. Karam & Christopher G. Wood & Nizar M. Tannir & Eric Jonasch & Jianjun Ga, 2021. "Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma," Nature Communications, Nature, vol. 12(1), pages 1-12, December.
    6. Mohammad Jaber & Ahmed Radwan & Netanel Loyfer & Mufeed Abdeen & Shulamit Sebban & Areej Khatib & Hazar Yassen & Thorsten Kolb & Marc Zapatka & Kirill Makedonski & Aurelie Ernst & Tommy Kaplan & Yosef, 2022. "Comparative parallel multi-omics analysis during the induction of pluripotent and trophectoderm states," Nature Communications, Nature, vol. 13(1), pages 1-21, December.
    7. Stefanie Hiltbrunner & Lena Cords & Sabrina Kasser & Sandra N. Freiberger & Susanne Kreutzer & Nora C. Toussaint & Linda Grob & Isabelle Opitz & Michael Messerli & Martin Zoche & Alex Soltermann & Mar, 2023. "Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype," Nature Communications, Nature, vol. 14(1), pages 1-14, December.
    8. Su Yin Lim & Elena Shklovskaya & Jenny H. Lee & Bernadette Pedersen & Ashleigh Stewart & Zizhen Ming & Mal Irvine & Brindha Shivalingam & Robyn P. M. Saw & Alexander M. Menzies & Matteo S. Carlino & R, 2023. "The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma," Nature Communications, Nature, vol. 14(1), pages 1-18, December.
    9. Michiel S. Heijden & Thomas Powles & Daniel Petrylak & Ronald Wit & Andrea Necchi & Cora N. Sternberg & Nobuaki Matsubara & Hiroyuki Nishiyama & Daniel Castellano & Syed A. Hussain & Aristotelis Bamia, 2022. "Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial," Nature Communications, Nature, vol. 13(1), pages 1-15, December.
    10. Yingying Shen & Chaojie Lu & Zhengbo Song & Chenxiao Qiao & Jiaoli Wang & Jinbiao Chen & Chengyan Zhang & Xianchang Zeng & Zeyu Ma & Tao Chen & Xu Li & Aifu Lin & Jufeng Guo & Jianli Wang & Zhijian Ca, 2022. "Ursodeoxycholic acid reduces antitumor immunosuppression by inducing CHIP-mediated TGF-β degradation," Nature Communications, Nature, vol. 13(1), pages 1-14, December.
    11. Isaac Dean & Colin Y. C. Lee & Zewen K. Tuong & Zhi Li & Christopher A. Tibbitt & Claire Willis & Fabrina Gaspal & Bethany C. Kennedy & Veronika Matei-Rascu & Rémi Fiancette & Caroline Nordenvall & Ul, 2024. "Rapid functional impairment of natural killer cells following tumor entry limits anti-tumor immunity," Nature Communications, Nature, vol. 15(1), pages 1-18, December.
    12. Lei Guan & Bin Wu & Ting Li & Lynn A. Beer & Gaurav Sharma & Mingyue Li & Chin Nien Lee & Shujing Liu & Changsong Yang & Lili Huang & Dennie T. Frederick & Genevieve M. Boland & Guangcan Shao & Tatyan, 2022. "HRS phosphorylation drives immunosuppressive exosome secretion and restricts CD8+ T-cell infiltration into tumors," Nature Communications, Nature, vol. 13(1), pages 1-12, December.
    13. Yi Zhang & Mingjie Wang & Ling Ye & Shengqi Shen & Yuxi Zhang & Xiaoyu Qian & Tong Zhang & Mengqiu Yuan & Zijian Ye & Jin Cai & Xiang Meng & Shiqiao Qiu & Shengzhi Liu & Rui Liu & Weidong Jia & Xianzh, 2024. "HKDC1 promotes tumor immune evasion in hepatocellular carcinoma by coupling cytoskeleton to STAT1 activation and PD-L1 expression," Nature Communications, Nature, vol. 15(1), pages 1-14, December.
    14. Rachael M. Zemek & Wee Loong Chin & Vanessa S. Fear & Ben Wylie & Thomas H. Casey & Cath Forbes & Caitlin M. Tilsed & Louis Boon & Belinda B. Guo & Anthony Bosco & Alistair R. R. Forrest & Michael J. , 2022. "Temporally restricted activation of IFNβ signaling underlies response to immune checkpoint therapy in mice," Nature Communications, Nature, vol. 13(1), pages 1-16, December.
    15. Jingjie Yi & Omid Tavana & Huan Li & Donglai Wang & Richard J. Baer & Wei Gu, 2023. "Targeting USP2 regulation of VPRBP-mediated degradation of p53 and PD-L1 for cancer therapy," Nature Communications, Nature, vol. 14(1), pages 1-17, December.
    16. Veronika Bandara & Jade Foeng & Batjargal Gundsambuu & Todd S. Norton & Silvana Napoli & Dylan J. McPeake & Timona S. Tyllis & Elaheh Rohani-Rad & Caitlin Abbott & Stuart J. Mills & Lih Y. Tan & Emma , 2023. "Pre-clinical validation of a pan-cancer CAR-T cell immunotherapy targeting nfP2X7," Nature Communications, Nature, vol. 14(1), pages 1-17, December.
    17. Yu-Ting Yen & May Chien & Pei-Yi Wu & Chi-Chang Ho & Chun-Te Ho & Kevin Chih-Yang Huang & Shu-Fen Chiang & K. S. Clifford Chao & William Tzu-Liang Chen & Shih-Chieh Hung, 2021. "Protein phosphatase 2A inactivation induces microsatellite instability, neoantigen production and immune response," Nature Communications, Nature, vol. 12(1), pages 1-14, December.
    18. Nicolas Allègre & Sabine Chauveau & Cynthia Dennis & Yoan Renaud & Dimitri Meistermann & Lorena Valverde Estrella & Pierre Pouchin & Michel Cohen-Tannoudji & Laurent David & Claire Chazaud, 2022. "NANOG initiates epiblast fate through the coordination of pluripotency genes expression," Nature Communications, Nature, vol. 13(1), pages 1-13, December.
    19. Jodi M. Carter & Saranya Chumsri & Douglas A. Hinerfeld & Yaohua Ma & Xue Wang & David Zahrieh & David W. Hillman & Kathleen S. Tenner & Jennifer M. Kachergus & Heather Ann Brauer & Sarah E. Warren & , 2023. "Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer," Nature Communications, Nature, vol. 14(1), pages 1-14, December.
    20. Fengqiao Li & Xue-Qing Zhang & William Ho & Maoping Tang & Zhongyu Li & Lei Bu & Xiaoyang Xu, 2023. "mRNA lipid nanoparticle-mediated pyroptosis sensitizes immunologically cold tumors to checkpoint immunotherapy," Nature Communications, Nature, vol. 14(1), pages 1-16, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-33793-w. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.